Phase III trial results of the R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax's Matrix-M adjuvant, has confirmed high efficacy and supported regulatory approvals ...
Feb 2, 2024
0
32
First boosters, second boosters, monovalent, bivalent. Just like the SARS-CoV-2 virus strain, the vaccines to combat the virus are always changing—and perhaps confusing.
Feb 2, 2024
0
65
Researchers have found that PD-1-enhanced DNA vaccination can induce sustained virus-specific CD8+ T cell immunity in an AIDS monkey model. The vaccinated monkeys remained free of AIDS for six years and achieved virologic ...
Feb 1, 2024
0
34
A single dose of the typhoid conjugate vaccine, Typbar TCV, provides lasting efficacy in preventing typhoid fever in children ages nine months to 12 years old, according to a new study conducted by researchers at University ...
Jan 25, 2024
0
38
It has been four years since the start of the COVID-19 pandemic. SARS-CoV-2 has yet to be eradicated and new variants are continuously emerging. Despite the extensive immunization programs, breakthrough infections (infection ...
Jan 19, 2024
1
57
After COVID vaccination, it usually takes weeks for our bodies to develop protective antibody responses. Imagine, however, a vaccine that speeds up the production of antibodies against SARS-CoV-2, the virus that spreads COVID-19.
Jan 17, 2024
0
36
Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. The ...
Jan 17, 2024
0
68
Staphylococcus aureus (SA) is an extremely common bacterial infection; about 30% of people have colonies of SA living in their nose. SA is often harmless, but it is also a leading cause of hospital-acquired and community-associated ...
Jan 16, 2024
0
26
Since the beginning of the COVID-19 pandemic, Raghavan Varadarajan, Professor at the Molecular Biophysics Unit (MBU), Indian Institute of Science (IISc), and collaborators have been working on developing a heat-tolerant vaccine ...
Jan 11, 2024
0
35
A team of scientists, led by Duke-NUS Medical School, has discovered a potential intranasal vaccine candidate that provides improved, longer-lasting immunity against SARS-CoV-2 viruses compared to when given as an injection. ...
Jan 9, 2024
0
156
